CEI International Affairs: European Proposal Courses | Click for more info
Follow
More…

National Cancer Institute CRO Aviano

Research Institute • Italy • 0 followers

Follow
More…

Latest Open Innovation Opportunities

  • Technology Offers (8)

Cell models to evaluate activity of p53:MDM2 inhibitors

Twist GAIN-of-function and LOSS-of-function cell models were developed and used for preclinical p53:MDM2 inhibitors evaluation, preliminary demonstrating that the expression of Twist hampers their efficacy. These findings support patient stratification on the basis of twist expression for treatment of a large fraction of sarcomas but also of a fraction of carcinomas. (Piccinin et al., Cancer Cell, 22, 404-415, Sept 11 2012).
  • +4 weeks
  • Hide post

Cell models to evaluate activity of p53:MDM2 inhibitors

Twist GAIN-of-function and LOSS-of-function cell models were developed and used for preclinical p53:MDM2 inhibitors evaluation, preliminary demonstrating that the expression of Twist hampers their efficacy. These findings support patient stratification on the basis of twist expression for treatment of a large fraction of sarcomas but also of a fraction of carcinomas. (Piccinin et al., Cancer Cell, 22, 404-415, Sept 11 2012).

Cell models to evaluate activity of p53:MDM2 inhibitors
  • +2 months
  • Hide post

HPLC device for high-volume samples analysis

Fluidic device that allows high sample volume injection in HPLC systems and provides an automated purification step, reducing sensitivity problems and facilitating the analysis of extracted compounds from complex matrix.
  • +6 months
  • Hide post

COGNITIVE FUNCTION SELF-ASSESSMENT TOOL

Novel tool for the evaluation of cognitive impairment that interfere with optimum quality of life: 18 items questionnaire with score correlated to clinical outcome and indications.
  • +6 months
  • Hide post

CHEMIOTHERAPY: IRINOTECAN DRUG MONITORING

The effectiveness of many anticancer drugs varies greatly from patient to patient and personalized dosages are required to avoid adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Irinotecan in patient's plasma and then to establish the optimal dose, with an on site test readable in real time.
  • +6 months
  • Hide post

CHEMIOTHERAPY: IMATINIB DRUG MONITORING

The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Imatinib in patient's plasma and then to establish the optimal dose, with an on site test readable in real time.
  • +6 months
  • Hide post

Mechanisms of p53 inactivation in TP53 wild type tumors and factors affecting sensitivity to MDM2 inhibitors

The research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack. The p53:MDM2 interplay is the target of a number of compounds currently under clinical trials. These compounds (MDM2i) are aimed at alleviating p53 from MDM2-mediated degradation and hence at restoring the p53 tumor suppressive activity. Maestro and coworkers gathered data indicating that the expression of Twist may significantly impact on the activity of these drugs.
  • +6 months
  • Hide post

Predictive Kit to identify patients non responding to platinum therapy

Predictive Kit to identify patients non responding to platinum therapy. 10 gene signature as a predictive biomarker for platinum treatment against different cancer types. The invention consists in quantifying the expression of 10 genes from tumor cells to detect patients eligible for platinum treatment at higher risk of developing drug resistance and disease progression. Drugs such as cisplatin, oxaliplatin and carboplatin are used to treat various types of worldwide common cancer, but resistance is a frequent event. Patient stratification based on tumor gene expression profile allows to personalize treatment reducing side effects and costs.
  • +6 months
  • Hide post

About

National Cancer Institute CRO-Aviano is an Italian public institute funded in 1984 and is committed to pursue excellence in all aspects of clinical oncology and management of health services. CRO is also an excellence in translational and clinical research activity. Our structure performs an average of 378740 patient exams/year, 8295 pts admitted/year (50% are extra-regional) for medium-long term stays and day hospital treatment. Scientific production sets above of 230 scientific papers in journals with Impact Factor (IF), ranking in the set of the 10% most cited papers in their respective scientific field, having a total IF>1000. Clinical trials average 60 per year.

Contact person

LUCIA CORAL

Knowledge Tranfer Manager at National Cancer Institute CRO Aviano
http://www.ricerca-cro.sanita.fvg.it/it/servizi_al_cittadino/technology_transfer.html
–
–
–
Research Institute
–
–

About our Innovation Strategy

We are currently seeking best-in-class collaboration partners for our publications listed in the tab Opportunities. We want to invite you to cooperate with us, so please repond to any of the opportunities by submitting one or more proposals. Our team will directly evaluate them and get back to you with a response. Please provide as much detailed non-confidential information as possible to facilitate the engagement process.

Research areas (9)

Biological SciencesGenome ResearchCellular and Molecular Biology MarketMedical Health relatedDiagnostic and 4 more

Latest Job Offers

National Cancer Institute CRO Aviano has't published any job offer yet

Latest Events

National Cancer Institute CRO Aviano hasn't published any Event yet

Related profiles

Innoget © 2020 Innoget